Benzinga | Nov 4, 2021 08:19AM EDT

Adaptimmune Therapeutics Q3 EPS $(0.30) Misses $(0.26) Estimate, Sales $1.20M Miss $1.37M Estimate

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 25 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $1.20 million which missed the analyst consensus estimate of $1.37 million by 12.19 percent. This is a 0.84 percent increase over sales of $1.19 million the same period last year.